|
|
Volumn 6, Issue 2, 2015, Pages 590-591
|
|
Aging interventions get human
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
EVEROLIMUS;
INFLUENZA VACCINE;
MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1;
METFORMIN;
PROGRAMMED DEATH 1 RECEPTOR;
RAPAMYCIN;
SULFONYLUREA;
PROTEIN KINASE INHIBITOR;
TARGET OF RAPAMYCIN KINASE;
AGING;
ANTIBODY TITER;
ANTINEOPLASTIC ACTIVITY;
ANTIVIRAL ACTIVITY;
CHRONIC DISEASE;
CLINICAL TRIAL (TOPIC);
DOSE RESPONSE;
DRUG APPROVAL;
DRUG DOSE INCREASE;
DRUG EFFICACY;
DRUG MEGADOSE;
DRUG RESEARCH;
DRUG TARGETING;
DRUG TOLERABILITY;
DRUG TREATMENT FAILURE;
DRUG USE;
EDITORIAL;
GERIATRIC CARE;
HEMAGGLUTINATION INHIBITION TEST;
HUMAN;
IMMUNOGENICITY;
IMMUNOPHENOTYPING;
IMMUNOSUPPRESSIVE TREATMENT;
INFECTION SENSITIVITY;
INFLUENZA;
INFLUENZA VACCINATION;
LIFE EXTENSION;
LOW DRUG DOSE;
METABOLIC SYNDROME X;
MORTALITY;
MOUSE MODEL;
MOUTH ULCER;
NON INSULIN DEPENDENT DIABETES MELLITUS;
NONHUMAN;
SENESCENCE;
SEROCONVERSION;
VIRUS STRAIN;
ANTAGONISTS AND INHIBITORS;
DRUG EFFECTS;
IMMUNITY;
HUMANS;
IMMUNITY;
PROTEIN KINASE INHIBITORS;
TOR SERINE-THREONINE KINASES;
|
|
EID: 84921754126
PISSN: None
EISSN: 19492553
Source Type: Journal
DOI: 10.18632/oncotarget.3173 Document Type: Editorial |
|
Times cited : (13)
|
|
References (7)
|
